Sterile PBS or 0.9% saline for reconstitution/dilution. It is recommended to use the reconstituted/diluted product within one month.
Belimumab/贝利尤单抗 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
Long Evans rats
Intermittent ocular hypertension model (iOHT)
Intravenous administration
10 mg/kg
Weekly for 6 weeks
To evaluate the effect of Belimumab on retinal ganglion cell and optic nerve axon loss induced by intermittent ocular hypertension. Results showed Belimumab treatment only slightly improved axonal survival and reduced serum IgG concentration but had limited impact on neurodegeneration.
J Neuroinflammation. 2016 Apr 18;13(1):82
Mice
Acute graft-versus-host disease (GVHD) model
Intraperitoneal injection
200 μg
Twice a week, until day 17 post-BMT
To evaluate the therapeutic effect of belimumab on acute GVHD. Results showed that belimumab treatment reduced the proportion of CD4+IL-17+ cells and increased the proportion of CD4+CD25+Foxp3+ Treg cells at day 17 post-BMT, improving GVHD scores. Additionally, belimumab modulated B-cell subsets, increasing mature B cells and decreasing memory B cells and plasma cells.
Front Immunol. 2022 Dec 6;13:995149
Human
Systemic lupus erythematosus patients
Intravenous
10 mg/kg
Monthly for more than 7 years
To investigate the effects of Belimumab on B cells in systemic lupus erythematosus patients, results showed that Belimumab treatment led to approximately 90% depletion of naive B cells and 60%-95% deletion of all other B cell subsets.
搜索
